The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.

```mdx

TL;DR

Hyperthermic intraperitoneal chemotherapy (HIPEC)—chemotherapy delivered heated directly into the abdomen during surgery—appears to offer survival benefits when combined with cytoreductive surgery in advanced ovarian cancer patients, though the evidence base remains limited and questions about optimal patient selection persist .

What the study found

Researchers conducted a systematic review of seven phase III randomized controlled trials examining HIPEC combined with cytoreductive surgery versus surgery alone in ovarian cancer. The analysis encompassed 1,252 patients (630 receiving HIPEC plus surgery, 622 receiving surgery alone), making this one of the largest evidence syntheses on the topic.

The core finding centers on timing and patient selection. HIPEC appears most beneficial in patients who demonstrate platinum sensitivity—meaning their cancer responds to initial platinum-based chemotherapy. When researchers examined progression-free survival (how long before cancer returns or worsens), patients receiving HIPEC showed meaningful improvements. Overall survival data were more mixed across trials, with some showing benefits while others found no significant difference. This variance matters: it suggests HIPEC works better in certain patient populations or clinical scenarios, but we haven't fully pinpointed which ones.

The review identified three clinical contexts where HIPEC is being tested: primary cytoreduction (surgery at initial diagnosis), interval debulking (surgery after several chemotherapy cycles), and secondary cytoreduction (surgery after relapse). The evidence quality differed across these scenarios. Primary and interval approaches showed more consistent benefit signals, while secondary cytoreduction data were sparser and more variable. This pattern suggests HIPEC may be most valuable earlier in treatment rather than at recurrence.

Safety emerged as a critical consideration. The review documented several potential complications: renal toxicity (kidney damage from chemotherapy absorption), gastrointestinal injury, and delayed recovery from surgery. These aren't rare exceptions—they represent real trade-offs that affect patient selection decisions. The authors emphasized that successful HIPEC programs depend heavily on technical expertise, proper patient selection, and rigorous perioperative care. A center performing HIPEC occasionally likely achieves different outcomes than one with established protocols and frequent use.

What this means for you

If you're managing advanced ovarian cancer or supporting someone who is:

HIPEC is not a standard-of-care replacement for conventional treatment. It remains an emerging technique offered at specialized centers, typically as part of clinical trials or at high-volume gynecologic oncology programs.

Platinum-responsive disease matters enormously. If your cancer responds well to initial platinum-based chemotherapy, you're in the population where HIPEC has shown the most promise. If you're platinum-resistant, the evidence for benefit is weaker.

Ask about trial eligibility. Because the evidence base is still building (phase III data, but relatively small individual trials), many centers offer HIPEC within structured research protocols rather than as routine practice. This isn't a limitation—it means your care contributes to better understanding while you potentially benefit.

Center experience matters. HIPEC involves specialized equipment, technical skill, and perioperative protocols. Outcomes likely depend on whether your surgical team regularly performs the procedure.

The survival benefit is real but modest. This isn't a breakthrough that transforms long-term outcomes for most patients. It's an incremental improvement for a subset of patients, in most trials measured in additional months rather than years.

Kidney function and gastrointestinal health need monitoring. If you proceed with HIPEC, baseline kidney function assessment and close follow-up for complications aren't optional—they're essential safeguards.

Study details

Aspect	Detail
Study type	Systematic review of phase III RCTs
Patient sample	1,252 patients with advanced ovarian cancer (630 HIPEC + surgery; 622 surgery alone)
Number of trials	7 phase III randomized controlled trials
Primary outcomes	Progression-free survival, overall survival
Secondary outcomes	Safety profile, quality of life, cost-effectiveness
Key finding	HIPEC shows progression-free survival benefit in platinum-sensitive patients; overall survival benefit variable across trials
Journal	Gynecologic Oncology
PubMed ID	40763418
Evidence tier	A tier (systematic review of phase III trials)

Sources

Primary source:

Systematic review: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer - PubMed ID 40763418, Gynecologic Oncology

Related reading on ovarian cancer management:

The review synthesizes seven phase III RCTs; consult the full text for individual trial citations and detailed methodology.

Note on interpretation:

This systematic review examined published phase III trial data. The conclusions are limited by trial heterogeneity (different chemotherapy regimens, surgical techniques, and patient populations across studies), relatively small individual trial sizes, and variable follow-up periods. Ongoing trials may refine which patient subgroups benefit most from HIPEC.

```

ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.